Trial
NCT05093387
SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
National Cancer Institute (NCI)
Condition
Anatomic Stage IV Breast Cancer AJCC v8
Intervention
Carboplatin
Why stopped
funding issues and pharmacy preparation for the drug
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-15